Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.
ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

On May 8, local time, at the ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Jian Zhang from Fudan University Shanghai Cancer Center delivered a rapid oral presentation of efficacy and safety results from the Phase II expansion cohort evaluating the PD-L1×VEGF-A bispecific antibody Pumitamig in combination with the TROP2 antibody-drug conjugate (ADC) BNT325 (sacituzumab drozuntecan) as first-line treatment for advanced or metastatic triple-negative breast cancer (a/mTNBC) (NCT05438329).
47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Yongsheng Wang from Shandong Cancer Hospital delivered a presentation entitled “Precision Decision-Making in Sentinel Lymph Node Biopsy”, offering an in-depth discussion on management strategies and individualized decision pathways for sentinel lymph node biopsy (SLNB).
Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on oncoplastic breast-conserving surgery and breast reconstruction techniques.
2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.
ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.
CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

CSCO BC 10th Anniversary Tribute · International Edition | Professor Zefei Jiang in Dialogue With Professor Michael Gnant: From SGBCC to CSCO BC—East-West Collaboration Shaping the Future of Breast Cancer Care

During the 2026 National Breast Cancer Conference, Professor Michael Gnant, President of the St. Gallen International Breast Cancer Conference (SGBCC), traveled across continents to participate in the event, further deepening collaboration between SGBCC and the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC).
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer

At the recently concluded ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Matteo Lambertini from IRCCS Ospedale Policlinico San Martino and the University of Genova served as one of the chairs of the session “Breast Cancer in Young Women (BCY) Session – Management of HR+ Breast Cancer in Young Women.” Together with fellow panelists, he participated in in-depth discussions on several key issues surrounding the management of breast cancer in young women.
ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues

At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to standard carboplatin chemotherapy could improve outcomes in patients with advanced breast cancer accompanied by chest wall disease (CWD), a population known for extremely poor prognosis and limited responsiveness to systemic therapy.
ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor Sung-Bae Kim spoke with Oncology Frontier and further elaborated on the key concepts presented in his talk.